Plain-English translation of NCT06209294 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether —a new immunotherapy drug—works better when combined with two standard chemotherapy medications (nab-paclitaxel and ) to shrink cervical cancer tumors before surgery. The goal is to help women with stage IB2-IB3 cervical cancer preserve their ability to have children by making tumors small enough that less aggressive surgery is needed. Researchers want to measure how well the medication shrinks tumors and whether it's safe to use.
Standard treatment for advanced cervical cancer often requires removing the uterus, which ends a woman's ability to become pregnant. This trial is exploring whether this new immunotherapy medication, combined with chemotherapy, can shrink tumors enough before surgery so that doctors can use fertility-preserving surgical techniques instead.
You likely qualify if…
You likely don't qualify if…
You will receive the new immunotherapy medication combined with two chemotherapy drugs before undergoing fertility-preserving surgery. The treatment period typically involves several cycles of medication delivered by infusion, with regular clinic visits for monitoring, blood tests, and imaging scans to track how well the tumor is shrinking. After the medication phase, you will have surgery designed to remove the cancer while preserving your uterus and fertility.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China